Aktienanalyse zu GSK plc (GSK)GSKGSK plc

GSK plc is a United Kingdom-based biopharma company. The Company is focused on the science of the immune system and advanced technologies, investing in four core therapeutic areas-respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its segments include Commercial Operations and Research and Development. Its specialty medicines prevent and treat diseases, from asthma, cancer and HIV to autoimmune diseases like lupus. General medicines include inhalers for asthma and chronic obstructive pulmonary disease (COPD) to antibiotics. It also owns ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody and HS235, a potential molecule for the treatment of pulmonary hypertension (PH). Its oncology portfolio also includes Zidesamtinib (NVL-520), neladalkib (NVL-655), and NVL-330. Its products include Anoro Ellipta, Apretude, Arexvy, Bexsero, Blenrep, Blujepa, Boostrix, Cervarix, Dovato, Efimosfermin, among others. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

GSK is currently not a strong buy due to its low RSI of 25.177, indicating oversold conditions, and a forward P/E of 9.7656, which suggests the stock may be undervalued. However, the recent 5-day change of -1.13% and a 20-day change of -3.39% indicate a downward trend, which could signal further price drops. The main risk is the current price being significantly below the 200-day SMA of 52.37, suggesting a potential for continued weakness in the near term.

4 analysts cover GSK: 1 rate it Buy, 3 Hold and 0 Sell. The average price target is 38.72.